PARIS--()--On June 28 and 29, academic thought leaders and high-ranking officers from pharma, biotech and information technology companies will gather in Paris at the 4th WIN Symposium to present and discuss breakthroughs that will bring personalized cancer medicine to the next phase. The Symposium will address new ways to advance individualized cancer therapy by applying new technologies, including targeted therapeutics and diagnostic biomarkers, and by designing and conducting innovative clinical trials in oncology. The program will include the first-ever disclosure of new technologies that are able to predict the efficacy of therapeutics for the treatment of cancer patients on an individual basis.
Both sides - academia and industry - will equally contribute to the presentations and discussions. Experts participating from the academic side include: James Doroshow (NCI), Ronald DePinho (USA), John Mendelsohn (USA); Alexander Eggermont (France); William Dalton (USA), Richard L. Schilsky (USA), Leroy Hood (Canada), and others. Industry will be represented by among others Brett Davis (Oracle Corporation), Richard Gaynor (Eli Lilly and Company), Steven Averbuch (Bristol-Myers Squibb), Nick Botwood (AstraZeneca), Paolo Paoletti (GlaxoSmithKline), and Christopher Viehbacher (Sanofi).
The program has received endorsements* by ASCO**, ESMO, UICC and INCa. It has been recognized as one of educational value for medical specialists, which is reflected by the awarding of 12 European CME credits and 17 ESMO MORA credits.
The 4th WIN Symposium is the next annual of the WIN Consortium (www.winconsortium.org), a joint initiative of Cancer Institute Gustave Roussy, France, and The University of Texas - MD Anderson Cancer Center, USA, which brings together 22 cancer centers from around the world and technology partners, including Agilent Technologies, GE Healthcare, Life Technologies, and Foundation Medicine.
Advance registration for the symposium at reduced rates remains open until June 24 via the WIN Consortium website. On-site registration in Paris will be open as of June 27.
(*) These endorsements do not constitute medical advice. Health care providers should exercise their own independent medical judgment.
(**) This program has the American Society of Clinical Oncology’s approval for quality of educational content. ASCO endorsement does not constitute medical advice. Health care providers should exercise their own independent medical judgment. ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50302449&lang=en
